SCHEMBL1007811

SCHEMBL1007811

OCCCCCCCCCOCCc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.50
LTA4H P09960 1/20 0.46
EPHX2 P34913 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
HRH3 Q9Y5N1 1/20 0.42
IDO1 P14902 1/20 0.42
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ADRB2 P07550 1/20 0.40
ADRB1 P08588 1/20 0.40
HTR1A P08908 1/20 0.40
CHRM5 P08912 1/20 0.40
ADRB3 P13945 1/20 0.40
DRD2 P14416 1/20 0.40
ADRA2B P18089 1/20 0.40
DRD4 P21917 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8673473 0.98 TDP1 (0.52) TDP1LTA4HEPHX2L3MBTL1MEN1
SCHEMBL97369 0.92 TDP1 (0.53) TDP1LTA4HEPHX2L3MBTL1MEN1
SCHEMBL1007405 0.92 IDO1 (0.52) TDP1LTA4HEPHX2L3MBTL1MEN1
SCHEMBL9574291 0.92 TDP1 (0.53) TDP1LTA4HEPHX2L3MBTL1MEN1
SCHEMBL3438759 0.92 IDO1 (0.52) TDP1LTA4HEPHX2L3MBTL1MEN1
SCHEMBL96692 0.92 TDP1 (0.53) TDP1LTA4HEPHX2L3MBTL1MEN1
SCHEMBL9574223 0.92 TDP1 (0.53) TDP1LTA4HEPHX2L3MBTL1MEN1
SCHEMBL1007629 0.92 IDO1 (0.52) TDP1LTA4HEPHX2L3MBTL1MEN1
SCHEMBL6268788 0.92 TDP1 (0.54) TDP1LTA4HEPHX2MEN1KMT2A
SCHEMBL97038 0.90 TDP1 (0.52) TDP1LTA4HEPHX2L3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2268606-B1 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-08-06 EP disclosed
US-8344027-B2 4-dimethylaminobutyric acid derivatives HOFFMANN-LA ROCHE INC. (US) 2013-01-01 US disclosed
US-20120289554-A1 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES ANDJELKOVIC MIRJANA (CH) 2012-11-15 US disclosed
EP-2268606-A1 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-01-05 EP disclosed
WO-2009132978-A1 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-11-05 WO disclosed
US-20090270505-A1 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270505-A1 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES CPT1B, CPT1A, CPT2 TDP1 2013/4885LTA4H 1137/4885EPHX2 2708/4885
US-20120289554-A1 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES CPT1B, CPT1A, CPT2 TDP1 2013/4885LTA4H 1137/4885EPHX2 2708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.